LY2456302
Pro00052483
Phase 1 small_molecule terminated
Quick answer
LY2456302 for Anxiety Disorders is a Phase 1 program (small_molecule) at Krystal Biotech Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Krystal Biotech Netherlands B.V.
- Indication
- Anxiety Disorders
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated